RT Journal Article
SR Electronic
T1 Protein Classifier for Thyroid Nodules Learned from Rapidly Acquired Proteotypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.09.20059741
DO 10.1101/2020.04.09.20059741
A1 Sun, Yaoting
A1 Selvarajan, Sathiyamoorthy
A1 Zang, Zelin
A1 Liu, Wei
A1 Zhu, Yi
A1 Zhang, Hao
A1 Chen, Hao
A1 Cai, Xue
A1 Gao, Huanhuan
A1 Wu, Zhicheng
A1 Chen, Lirong
A1 Teng, Xiaodong
A1 Zhao, Yongfu
A1 Mantoo, Sangeeta
A1 Lim, Tony Kiat-Hon
A1 Hariraman, Bhuvaneswari
A1 Yeow, Serene
A1 bin Syed Abdillah, Syed Muhammad Fahmy
A1 Lee, Sze Sing
A1 Ruan, Guan
A1 Zhang, Qiushi
A1 Zhu, Tiansheng
A1 Wang, Weibin
A1 Wang, Guangzhi
A1 Xiao, Junhong
A1 He, Yi
A1 Wang, Zhihong
A1 Sun, Wei
A1 Qin, Yuan
A1 Xiao, Qi
A1 Zheng, Xu
A1 Wang, Linyan
A1 Zheng, Xi
A1 Xu, Kailun
A1 Shao, Yingkuan
A1 Liu, Kexin
A1 Zheng, Shu
A1 Aebersold, Ruedi
A1 Li, Stan Z.
A1 Kon, Oi Lian
A1 Iyer, N. Gopalakrishna
A1 Guo, Tiannan
YR 2020
UL http://medrxiv.org/content/early/2020/04/16/2020.04.09.20059741.abstract
AB Up to 30% of thyroid nodules cannot be accurately classified as benign or malignant by cytopathology. Diagnostic accuracy can be improved by nucleic acid-based testing, yet a sizeable number of diagnostic thyroidectomies remains unavoidable. In order to develop a protein classifier for thyroid nodules, we analyzed the quantitative proteomes of 1,725 retrospective thyroid tissue samples from 578 patients using pressure-cycling technology and data-independent acquisition mass spectrometry. With artificial neural networks, a classifier of 14 proteins achieved over 93% accuracy in classifying malignant thyroid nodules. This classifier was validated in retrospective samples of 271 patients (91% accuracy), and prospective samples of 62 patients (88% accuracy) from four independent centers. These rapidly acquired proteotypes and artificial neural networks supported the establishment of an effective protein classifier for classifying thyroid nodules.Competing Interest StatementThe research group of T.G. is supported by Pressure Biosciences Inc, which provides sample preparation instrumentation.Funding StatementThis work was supported by grants from National Natural Science Foundation of China (81972492) and National Natural Science Fund for Young Scholars (21904107), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement Program (20190101A04). Further support for this project was obtained from the National Cancer Centre Research Fund (Peter Fu Program) and National Medical Research Council Clinician-Scientist Award (NMRC/CSAINV/011/2016), both in Singapore. The prospective study was supported by National Natural Science Foundation of China (81902726), China Postdoctoral Science Foundation (NO. 2018M641739), Natural Science Foundation of Liaoning Province (20180530090).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material. MS raw data were deposited in iProX (IPX000444000). All the data will be publicly released upon publication.